Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot - AstraZeneca (NYSE:AZN), GSK

GlaxoSmithKline Plc (NYSE:GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co.
The study will enroll 4,000 participants and compare the shot to Oxford University - AstraZeneca Plc (NASDAQ:AZN).
The trial will test SK's protein-based vaccine candidate, GBP510, in combination with Glaxo, providing an adjuvant that can enhance the response to vaccines.
Results from the Phase 3 study are expected in 1H of 2022, after which, subject to positive outcomes and regulatory approval, the vaccine is expected to be supplied at scale worldwide through the COVAX facility.
Glaxo has been developing adjuvants for other vaccines developed by Sanofi SA (NASDAQ:SNY) and Medicago.
Related Content: Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Also Read: GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine
GSK is also working with CureVac BV (NASDAQ:CVAC) to jointly develop next-generation mRNA vaccines for COVID-19 to tackle multiple emerging variants in one vaccine.
Related: GlaxoSmithKline, CureVac In Pact To Develop Vaccines For COVID-19 Variants
Price Action: GSK shares are down 0.81% at $40.58 during the premarket session on the last check Tuesday.
Photo by hakan german from Pixabay

To add Benzinga News as your preferred source on Google, click here.